Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -37.07% is 29% above its 5-year average of -52.03%, near the high end of its 5-year range (-131.17%–-19.27%).
35.94% below its 12-month average of -27.27%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.98%.
RETURN ON ASSETS (ROA)
-37.07%
RETURN ON ASSETS (ROA) AVG TTM
-27.27%
RETURN ON ASSETS (ROA) AVG 3Y
-64.53%
RETURN ON ASSETS (ROA) AVG 5Y
-52.03%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-35.94%
CURRENT VS 3Y AVG
+42.55%
CURRENT VS 5Y AVG
+28.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.47%
median of 682 covered companies
CURRENT VS SECTOR MEDIAN
-21.66%
vs the sector median at left
Inhibikase Therapeutics, Inc.
Market Cap
$263.39M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
Market Cap
$262.11M
Return on Assets (ROA)
-25.09%
TTM Avg
-72.59%
3Y Avg
-80.80%
5Y Avg
-146.30%
Market Cap
$264.62M
Return on Assets (ROA)
-34.24%
TTM Avg
-52.06%
3Y Avg
-53.17%
5Y Avg
-44.53%
Market Cap
$260.03M
Return on Assets (ROA)
-29.15%
TTM Avg
-33.84%
3Y Avg
-33.85%
5Y Avg
-31.54%
Market Cap
$267.17M
Return on Assets (ROA)
-35.96%
TTM Avg
-58.88%
3Y Avg
-82.10%
5Y Avg
-113.46%
Market Cap
$267.82M
Return on Assets (ROA)
-13.63%
TTM Avg
-10.56%
3Y Avg
-3.47%
5Y Avg
-3.69%
Market Cap
$258.56M
Return on Assets (ROA)
-2.06%
TTM Avg
-16.77%
3Y Avg
-17.09%
5Y Avg
-12.28%
Market Cap
$256.22M
Return on Assets (ROA)
-38.25%
TTM Avg
-20.05%
3Y Avg
-26.23%
5Y Avg
-29.50%
Market Cap
$271.23M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $263.39M | -37.07% | -27.27% | -64.53% | -52.03% |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | -25.09% | -72.59% | -80.80% | -146.30% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $264.62M | -34.24% | -52.06% | -53.17% | -44.53% |
| AC Immune S.A. (ACIU)vs › | $260.03M | -29.15% | -33.84% | -33.85% | -31.54% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $267.17M | -35.96% | -58.88% | -82.10% | -113.46% |
| OraSure Technologies, Inc. (OSUR)vs › | $267.82M | -13.63% | -10.56% | -3.47% | -3.69% |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.56M | -2.06% | -16.77% | -17.09% | -12.28% |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | -38.25% | -20.05% | -26.23% | -29.50% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $271.23M | -134.38% | -47.50% | -42.91% | -40.55% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $249.41M | -34.55% | -30.02% | -24.36% | -21.40% |
ROA
-37.1%
ROE
-39.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -26.63% |
| 2024-12-31 | -27.91% |
| 2023-12-31 | -131.17% |
| 2022-12-31 | -72.40% |
| 2021-12-31 | -34.82% |
| 2020-12-31 | -19.27% |
| 2019-12-31 | -14960.48% |
| 2018-12-31 | -75.62% |
| 2017-12-31 | -152.92% |
| 2016-12-31 | -385.90% |
